JOURNAL
Current Issue
Journal Archive
 

Chief Editor -
Abdulrazak Abyad MD, MPH, MBA, AGSF, AFCHSE

.........................................................

Publisher -
Lesley Pocock
medi+WORLD International
AUSTRALIA
Email
: lesleypocock@mediworld.com.au
publishermwi@gmail.com
.........................................................

Editorial Enquiries -
abyad@cyberia.net.lb
.........................................................

Advertising Enquiries -
lesleypocock@mediworld.com.au
.........................................................

While all efforts have been made to ensure the accuracy of the information in this journal, opinions expressed are those of the authors and do not necessarily reflect the views of The Publishers, Editor or the Editorial Board. The publishers, Editor and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; or the views and opinions expressed. Publication of any advertisements does not constitute any endorsement by the Publishers and Editors of the product advertised.

The contents of this journal are copyright. Apart from any fair dealing for purposes of private study, research, criticism or review, as permitted under the Australian Copyright Act, no part of this program may be reproduced without the permission of the publisher.

WFM / MEJFM November 2024

Metformin in the treatment of cirrhosis


Mehmet Rami Helvaci (1), Hulya Halici (2) , Kevser Erdogan (3), Alper Sevinc (1), Celaletdin Camci (1), Abdulrazak Abyad (4), Lesley Pocock (5)

(1) Specialist of Internal Medicine, MD, Turkey
(2) Manager of Writing and Statistics, Turkey
(3) Specialist of Public Health, MD, Turkey
(4) Middle-East Academy for Medicine of Aging, MD, Lebanon
(5) medi-WORLD International, Australia

Corresponding author:
Prof Dr Mehmet Rami Helvaci
07400, ALANYA, Turkey
Phone: 00-90-506-4708759
Email: mramihelvaci@hotmail.com


Received: September 2024. Accepted: October 2024; Published: November 1, 2024.Citation: Helvaci MR et al. Metformin in the treatment of cirrhosis. World Family Medicine. November 2024; 22(10): 6-20 DOI: 10.5742/MEWFM.2024.95257841


Abstract


Background: Hardened red blood cells (RBC)-induced capillary endothelial damage initiating at birth terminates with atherosclerotic end-organ failures in much earlier ages of life in sickle cell diseases (SCD).

Methods: All patients with the SCD were included.

Results: We studied 222 males and 212 females with similar mean ages (30.8 vs 30.3 years, p>0.05, respectively). Smoking (23.8% vs 6.1%, p<0.001), alcohol (4.9% vs 0.4%, p<0.001), transfused RBC in their lives (48.1 vs 28.5 units, p=0.000), disseminated teeth losses (5.4% vs 1.4%, p<0.001), ileus (7.2% vs 1.4%, p<0.001), cirrhosis (8.1% vs 1.8%, p<0.001), chronic obstructive pulmonary disease (25.2% vs 7.0%, p<0.001), leg ulcers (19.8% vs 7.0%, p<0.001), digital clubbing (14.8% vs 6.6%, p<0.001), coronary heart disease (18.0% vs 13.2%, p<0.05), chronic renal disease (9.9% vs 6.1%, p<0.05), and stroke (12.1% vs 7.5%, p<0.05) were all higher in males.

Conclusion: SCD terminate with an accelerated atherosclerotic process in whole body, and cirrhosis may just be one of the several consequences of systemic atherosclerosis. Excess fat tissue may be much more important than alcohol and smoking for the development of cirrhosis all over the world at the moment. The efficacy of metformin in loss of appetite is well knownin the literature. Since metformin is a safe, cheap, orally used, and effective drug for the treatment of excess weight, it should be advised in cirrhosis even in patients with the normal weight since there are approximately 20 kg of excess fat tissue even between the upper and lower borders of normal weight in adults.

Key words: Sickle cell diseases, cirrhosis, excess fat tissue, alcohol, smoking,
vascular endothelial inflammation, systemic atherosclerosis





.................................................................................................................

I About MEJFM I Journal I Advertising I Author Info I Editorial Board I Resources I Contact us I Journal Archive I MEPRCN I Noticeboard I News and Updates
Disclaimer - ISSN 148-4196 - © Copyright 2007 medi+WORLD International Pty. Ltd. - All rights reserved